Shop by Category

  • ADC and Other Drug Conjugate (ODC) Solutions
  • AqT® Reagents and Kits
  • Services
  • Standards and Controls
  • Biotin and Streptavidin/Avidin
  • Enzyme
  • Antibody
  • Nucleic Acid and Oligo
  • Peptide and Protein
  • Small Molecule
  • Assay, Buffers and Others
  • Membrane Protein and GPCR Related
  • Solid Support

    • Shop by Brand

  • PerKit®
  • SepSphere™
  • AqT®
  • oxLink™
  • sxLink™
  • View all Brands
  • ADC and Other Drug Conjugate (ODC) Solutions
  • AqT® Reagents and Kits
  • Services
  • Standards and Controls
  • Biotin and Streptavidin/Avidin
  • Enzyme
  • Antibody
  • Nucleic Acid and Oligo
  • Peptide and Protein
  • Small Molecule
  • Assay, Buffers and Others
  • Membrane Protein and GPCR Related
  • Solid Support

    • Shop by Brand

  • PerKit®
  • SepSphere™
  • AqT®
  • oxLink™
  • sxLink™
  • View all Brands

    • ADC and Other Drug Conjugate (ODC) Solutions

    Prepare Your Own Custom Drug-Conjugates for Screening and Proof-of-Concept with CellMosaic’s Personalized Kits (PerKit®)

    Since 2017, CellMosaic has provided PerKits® to help life science customers quickly evaluate their biologics of interest (such as antibodies, proteins, peptides, and oligonucleotides) through direct conjugation with a range of key payloads (e.g., chemotherapeutic drugs and toxins) using traditional linker chemistry. The kits are available in various configurations, offering multiple conjugation strategies. Some drug conjugation kits are compatible with general payloads containing specific functional groups, such as carboxylic acids or amines, while others provide selected, standard linkage molecules conjugated to a specific payload. These kits include appropriate reactive modifications to directly attach the payload and linker to the biologic of interest. Each kit includes all necessary reagents and procedures for attaching the selected payload to the customer's biologics and for purifying the final drug conjugates. Customers need only supply their biologics and standard lab equipment.

    As of August 2024, customers from over 112 organizations worldwide have used CellMosaic's ADC kits.

    For publications using CellMosaic's ADC kits, click here.

    PerKit® Drug Conjugation Selection Guide

    Product#
    Drug
    Mechanism of Action
    Protein
    Labeling Chemistry
    Linkage
    Scale of Reaction (Standard Kit)
    CM11431 Deruxtecan Topoisomerase I Inhibitor  IgG Ab Reduced thiol Releasable (GGFG) 1-3 mg
    CM11434 Deruxtecan (HL) Topoisomerase I Inhibitor  IgG Ab Reduced thiol Releasable (GGFG) 1-3 mg
    CM11432 Deruxtecan Topoisomerase I Inhibitor Any protein Surface amine Releasable (GGFG) 6.67-20 nmol
    CM11435 Exatecan Topoisomerase I Inhibitor Ab or Protein Surface amine Stable 6.67-20 nmol
    CM11436 Exatecan Topoisomerase I Inhibitor Ab or Protein Surface amine Releasable (VC-PAB) 6.67-20 nmol
    CM11408 SN38 Topoisomerase I Inhibitor  IgG Ab Surface amine Releasable (ester) 1-3 mg
      CM11430 SN38 Topoisomerase I Inhibitor Any protein Surface amine Releasable (ester) 6.67-20 nmol
    CM11438 SN38 Topoisomerase I Inhibitor Ab or Protein Surface amine Releasable (VC-PAB) 6.67-20 nmol
     CM11410 DM1 Tubulin Polymerization Inhibitor  IgG Ab Surface amine Stable 0.1 mg, 1-3 mg
     CM11419 DM1 Tubulin Polymerization Inhibitor  F(ab')2 Surface amine Stable  0.73-2.2 mg
    CM11414 DM1 Tubulin Polymerization Inhibitor Any protein  Surface amine Stable  6.67-20 nmol
    CM11409 MMAE Tubulin Polymerization Inhibitor  IgG Ab Reduced thiol Releasable (VC-PAB) 0.1 mg, 1-3 mg
     CM11416 MMAE Tubulin Polymerization Inhibitor  F(ab')2 Reduced thiol Releasable (VC-PAB)  0.73-2.2 mg
     CM11413 MMAE Tubulin Polymerization Inhibitor Any protein  Surface amine Releasable (VC-PAB)  0.73-2.2 mg
     CM11422 MMAF Tubulin Polymerization Inhibitor  IgG Ab Reduced thiol Stable 1-3 mg
     CM11425 MMAF Tubulin Polymerization Inhibitor  IgG Ab Reduced thiol Releasable (VC-PAB) 1-3 mg
     CM11407 Methotrexate  Dihydrofolate Reductase (DHFR) Inhibitor  IgG Ab Surface amine  Stable  1-3 mg
     CM11406 Doxorubicin DNA Intercalation, Topoisomerase II inhibitor  IgG Ab Surface amine  Stable  1-3 mg
    CM11433 UM171 Proteasomal Degradation  IgG Ab Surface amine  Stable  1-3 mg
    CM11439 PBD Dimer DNA Binding Ab or Protein Surface amine Releasable (VA) 6.67-20 nmol
     CM11429 No drug (VC-PAB linker only) No drug (VC-PAB linker only)  IgG Ab Reduced thiol Releasable (VC-PAB) 1-3 mg
     CM51403  Acid N/A (Customer Supplied)  IgG Ab Surface amine  Stable  1-3 mg
     CM52408  Acid N/A (Customer Supplied) Any protein  Surface amine  Stable   15-50 nmol
    (Note: Additional kit configurations can be added upon customer request. Please inquire if your desired configuration is not listed, or request a custom bioconjugation service.)

     

    Bioconjugate Drug Development & Manufacturing

    CellMosaic is a premier service provider, offering expertise in all drug conjugation-related services, particularly for projects requiring complex chemistry, larger product volumes, or stringent specifications for the final product. CellMosaic’s services encompass all standard, non-proprietary conjugations.

    Learn More

     

    AqueaTether® Technology

    When a drug conjugate cannot be synthesized using classical linkers, or when the effectiveness of the drug conjugate is compromised by the number of toxins loaded onto the antibody, CellMosaic has developed novel, super-hydrophilic, high-loading AqueaTether® (AqT®) linkers to address these challenges.

    For more information about AqT® technologies, click here.

    To learn how to access this technology for your novel ADC development, Learn more here.

     

    Compare Selected